of diluted solution) 0.01 mg to 0.2 mg (0.5 ml to 10 ml of diluted solution) intravenous infusion dilute 10 ml (2 mg) in 500 ml of 5% dextrose injection, usp 5 mcg/min. (1.25 ml of diluted solution per minute) intramuscular use solution undiluted 0.2 mg (1 ml) 0.02 mg to 1 mg (0.1 ml to 5 ml) subcutaneous use solution undiluted 0.2 mg (1 ml) 0.15 mg to 0.2 mg (0.75 ml to 1 ml) intracardiac use solution undiluted 0.02 mg (0.1 ml) there are no well-controlled studies in children to establish appropriate dosing; however, the american heart association recommends an initial infusion rate of 0.1 mcg/kg/min, with the usual range being 0.1 mcg/kg/min to 1 mcg/kg/min. recommended dosage for adults with shock and hypoperfusion states: † concentrations up to 10 times greater have been used when limitation of volume is essential. †† rates over 30 mcg per minute have been used in advanced stages of shock. the rate of infusion should be adjusted on the basis of heart rate, central venous pressure, systemic blood pressure, and urine flow. if the heart rate exceeds 110 beats per minute, it may be advisable to decrease or temporarily discontinue the infusion. route of administration preparation of dilution † infusion rate †† intravenous infusion dilute 5 ml (1 mg) in 500 ml of 5% dextrose injection, usp 0.5 mcg to 5 mcg per minute (0.25 ml to 2.5 ml of diluted solution) recommended dosage for adults with bronchospasm occurring during anesthesia: route of administration preparation of dilution initial dose subsequent dose bolus intravenous injection dilute 1 ml (0.2 mg) in 9 ml of sodium chloride injection, usp, or 5% dextrose injection, usp 0.01 mg to 0.02 mg (0.5 ml to 1 ml of diluted solution) the initial dose may be repeated when necessary parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. such solution should not be used.

rointestinal smooth muscle. it prevents or relieves bronchoconstriction, but tolerance to this effect develops with overuse of the drug. in man, isoproterenol causes less hyperglycemia than does epinephrine. isoproterenol and epinephrine are equally effective in stimulating the release of free fatty acids and energy production. absorption, fate, and excretion . isoproterenol is metabolized primarily in the liver and other tissues by comt. isoproterenol is a relatively poor substrate for mao and is not taken up by sympathetic neurons to the same extent as are epinephrine and norepinephrine. the duration of action of isoproterenol may therefore be longer than that of epinephrine, but is still brief.